Stephen F. Betz - 26 Dec 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Scientific Officer
Signature
/s/ Tobin Schilke, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
26 Dec 2025
Net transactions value
+$34,380
Form type
4
Filing time
29 Dec 2025, 16:36:41 UTC
Previous filing
16 Jun 2025
Next filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Betz Stephen F. Chief Scientific Officer C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO /s/ Tobin Schilke, as attorney-in-fact 29 Dec 2025 0001886575

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $34,380 +18,000 +18% $1.91 117,713 26 Dec 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Options Exercise $0 -18,000 -17% $0.000000 90,514 26 Dec 2025 Common Stock 18,000 $1.91 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested in 48 equal monthly installments beginning on April 16, 2018.